About this trial
Aortic stenosis is a common disease with increasing prevalence due to an aging population. Aortic valve replacement is indicated for symptomatic severe aortic stenosis. Leisure activities and tourism at high altitude destinations are popular but may impose a higher risk to patients with aortic stenosis. Pathophysiological considerations led to an expert consensus to avoid high altitude exposure, though there is no robust scientific evidence.
Hence, the objective of this study is to evaluate the safety of high altitude exposure in patients with asymptomatic moderate or severe aortic stenosis by the measurement of surrogate markers for cardiac adverse events such as the decrease in exercise capacity, the assessment of changes in cardiac filling pressures, cardiac dimensions and function, and the evaluation of the incidence of cardiac arrhythmia.
Eligibility criteria
Qualifiers
Moderate or severe aortic stenosis (aortic valve area (AVA) ≤1.5 cm2)
NYHA class I
LVEF > 50%
Aortic stenosis staging classification Stage 0 or 1
Disqualifiers
NYHA class > I (all groups)
History of cardiac decompensation requiring hospitalization (all groups)
Uncontrolled arterial hypertension (>180/100 mmHg at rest) (all groups)
Other Cardiomyopathies w/ normal LVEF (dilatative, hypertrophic, infiltrative CMP) (all groups)
Trial design
Treatments tested in this trial
- Participants will be escorted to high altitude and undergo a series of test